Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DEXAMETHASONE

Form:

8 of 8 products shown

6 general benefit · 2 not a benefit

Other products in the same Health Canada class (H02AB, S01BA) — coverage varies; not interchangeable

  • Fluorometholone (Fml): general benefit
  • Fluorometholone (Flarex): general benefit
  • Hydrocortisone (Cortef): general benefit, Listing status unconfirmed
  • Methylprednisolone (Medrol): general benefit
  • Methylprednisolone (Depo-Medrol): general benefit
  • Prednisolone (Pred Forte): general benefit, Not a benefit

7 more in the class list below

Maxidex · DIN 00042579 · 0.1% · Oph Oint-3.5g Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Maxidex · DIN 00042579 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-01-19 · brand MAXIDEX · ATC S01BA01 DEXAMETHASONE · form Ointment · route Ophthalmic · ingredients DEXAMETHASONE 0.1 %/W/W · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Maxidex: Formulary list price $9.7200/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.7200 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4591 · Verify on the e-Formulary ↗ (DIN 00042579)

Source record
DIN 00042579: Maxidex Raw flags: sec3=Y Item: 520800015; group id 592; item number 1550; lccId None; manufacturer id NOV Source form: Oph Oint-3.5g Pk; strength: 0.1% Recorded listing: General benefit Source prices (unrounded): $9.7200; ministry $9.7200 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00042579 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4591
Shortage status: resolved shortage (ended 2025-12-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00042579
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Maxidex · DIN 00042560 · 0.1% · Oph suspension

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Maxidex · DIN 00042560 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-02-22 · brand MAXIDEX · ATC S01BA01 DEXAMETHASONE · form Suspension · route Ophthalmic · ingredients DEXAMETHASONE 0.1 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Maxidex: Formulary list price $1.7900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.7900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2620 · Verify on the e-Formulary ↗ (DIN 00042560)

Source record
DIN 00042560: Maxidex Raw flags: sec3=Y Item: 520800014; group id 592; item number 1551; lccId None; manufacturer id NOV Source form: Oph Susp; strength: 0.1% Recorded listing: General benefit Source prices (unrounded): $1.7900; ministry $1.7900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00042560 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2620
Shortage status: resolved shortage (ended 2022-11-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00042560
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Dexamethasone · DIN 02261081 · 0.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Dexamethasone · DIN 02261081 Manufacturer: Apotex Inc.; listing date 2005-04-28 Health Canada: Marketed since 2004-11-17 · brand APO-DEXAMETHASONE · ATC H02AB02 DEXAMETHASONE · form Tablet · route Oral · ingredients DEXAMETHASONE 0.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Dexamethasone: Formulary list price $0.1564/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1564 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74650 · Verify on the e-Formulary ↗ (DIN 02261081)

Source record
DIN 02261081: Apo-Dexamethasone Raw flags: sec3=Y Item: 680400022; group id 707; item number 1746; lccId None; manufacturer id APX Source form: Tab; strength: 0.5mg Recorded listing: General benefit Source prices (unrounded): $0.1564; ministry $0.1564 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02261081 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74650
Interchangeable products
Decadron · DIN 00016462 · not recorded PMS-Dexamethasone · DIN 01964976 · $0.1564
Shortage status: resolved shortage (ended 2020-09-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02261081
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Dexamethasone · DIN 01964976 · 0.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Dexamethasone · DIN 01964976 Manufacturer: Pharmascience Inc.; listing date 1998-12-31 Health Canada: Marketed since 2023-10-11 · brand PMS-DEXAMETHASONE · ATC H02AB02 DEXAMETHASONE · form Tablet · route Oral · ingredients DEXAMETHASONE 0.5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Dexamethasone: Formulary list price $0.1564/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1564 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=23261 · Verify on the e-Formulary ↗ (DIN 01964976)

Source record
DIN 01964976: PMS-Dexamethasone Raw flags: sec3=Y Item: 680400022; group id 707; item number 1746; lccId None; manufacturer id PMS Source form: Tab; strength: 0.5mg Recorded listing: General benefit Source prices (unrounded): $0.1564; ministry $0.1564 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01964976 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=23261
Interchangeable products
Apo-Dexamethasone · DIN 02261081 · $0.1564 Decadron · DIN 00016462 · not recorded
Shortage status: resolved shortage (ended 2023-04-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01964976
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Dexamethasone · DIN 02250055 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Dexamethasone · DIN 02250055 Manufacturer: Apotex Inc.; listing date 2004-10-14 Health Canada: Marketed since 2004-03-08 · brand APO-DEXAMETHASONE · ATC H02AB02 DEXAMETHASONE · form Tablet · route Oral · ingredients DEXAMETHASONE 4 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Dexamethasone: Formulary list price $0.6112/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6112 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73487 · Verify on the e-Formulary ↗ (DIN 02250055)

Source record
DIN 02250055: Apo-Dexamethasone Raw flags: sec3=Y Item: 680400031; group id 707; item number 1747; lccId None; manufacturer id APX Source form: Tab; strength: 4mg Recorded listing: General benefit Source prices (unrounded): $0.6112; ministry $0.6112 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02250055 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73487
Interchangeable products
Decadron · DIN 00354309 · not recorded PMS-Dexamethasone · DIN 01964070 · $0.6112
Shortage status: resolved shortage (ended 2025-10-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02250055
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Dexamethasone · DIN 01964070 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Dexamethasone · DIN 01964070 Manufacturer: Pharmascience Inc.; listing date 1998-12-31 Health Canada: Marketed since 2023-10-11 · brand PMS-DEXAMETHASONE · ATC H02AB02 DEXAMETHASONE · form Tablet · route Oral · ingredients DEXAMETHASONE 4 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Dexamethasone: Formulary list price $0.6112/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6112 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=23194 · Verify on the e-Formulary ↗ (DIN 01964070)

Source record
DIN 01964070: PMS-Dexamethasone Raw flags: sec3=Y Item: 680400031; group id 707; item number 1747; lccId None; manufacturer id PMS Source form: Tab; strength: 4mg Recorded listing: General benefit Source prices (unrounded): $0.6112; ministry $0.6112 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01964070 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=23194
Interchangeable products
Apo-Dexamethasone · DIN 02250055 · $0.6112 Decadron · DIN 00354309 · not recorded
Shortage status: resolved shortage (ended 2020-09-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01964070
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Decadron · DIN 00016462 · 0.5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.Discontinued 2002-07-29 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Decadron · DIN 00016462 Manufacturer: Merck Sharp & Dohme Canada, Division of Merck Frosst Canada; listing date 1996-10-01 Health Canada: Cancelled post market since 2002-07-29 · brand DECADRON TAB 0.5MG · ATC H02AB02 DEXAMETHASONE · form Tablet · route Oral · ingredients DEXAMETHASONE .5 MG · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Check this DIN again · Health Canada product record

Decadron: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=286 · Verify on the e-Formulary ↗ (DIN 00016462)

Source record
DIN 00016462: Decadron Raw flags: notABenefit=Y, sec3=Y Item: 680400022; group id 707; item number 1746; lccId None; manufacturer id MSD Source form: Tab; strength: 0.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00016462 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=286
Interchangeable products
Apo-Dexamethasone · DIN 02261081 · $0.1564 PMS-Dexamethasone · DIN 01964976 · $0.1564
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00016462
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.

Decadron · DIN 00354309 · 4mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-08-08 — choose a marketed DIN from the same-category list.Discontinued 2003-08-08 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-08-08 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-08-08 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Decadron · DIN 00354309 Manufacturer: Merck Sharp & Dohme Canada, Division of Merck Frosst Canada; listing date 1996-10-01 Health Canada: Cancelled post market since 2003-08-08 · brand DECADRON TAB 4MG · ATC H02AB02 DEXAMETHASONE · form Tablet · route Oral · ingredients DEXAMETHASONE 4 MG · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Check this DIN again · Health Canada product record

Decadron: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2533 · Verify on the e-Formulary ↗ (DIN 00354309)

Source record
DIN 00354309: Decadron Raw flags: notABenefit=Y, sec3=Y Item: 680400031; group id 707; item number 1747; lccId None; manufacturer id MSD Source form: Tab; strength: 4mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00354309 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2533
Interchangeable products
Apo-Dexamethasone · DIN 02250055 · $0.6112 PMS-Dexamethasone · DIN 01964070 · $0.6112
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00354309
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2003-08-08 — choose a marketed DIN from the same-category list.

DEXAMETHASONE 21-PHOSPHATE

2 general benefit · 1 not a benefit

Other products in the same Health Canada class (H02AB, S01BA) — coverage varies; not interchangeable

  • Fluorometholone (Fml): general benefit
  • Fluorometholone (Flarex): general benefit
  • Hydrocortisone (Cortef): general benefit, Listing status unconfirmed
  • Methylprednisolone (Medrol): general benefit
  • Methylprednisolone (Depo-Medrol): general benefit
  • Prednisolone (Pred Forte): general benefit, Not a benefit

7 more in the class list below

Dexamethasone Sodium · DIN 00664227 · 4mg/mL · injection solution

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dexamethasone Sodium · DIN 00664227 Manufacturer: Sandoz Canada Inc.; listing date 1998-12-31 Health Canada: Marketed since 2005-09-01 · brand DEXAMETHASONE SODIUM PHOSPHATE INJ USP 4MG/ML · ATC H02AB02 DEXAMETHASONE · form Solution · route Intramuscular, Intrasynovial, Intravenous · ingredients DEXAMETHASONE PHOSPHATE (DEXAMETHASONE SODIUM PHOSPHATE) 4 MG/ML · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Dexamethasone Sodium: Formulary list price $1.6900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6593 · Verify on the e-Formulary ↗ (DIN 00664227)

Source record
DIN 00664227: Dexamethasone Sodium Raw flags: sec3=Y Item: 680400005; group id 708; item number 1748; lccId None; manufacturer id SDZ Source form: Inj Sol; strength: 4mg/mL Recorded listing: General benefit Source prices (unrounded): $1.6900; ministry $1.6900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00664227 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6593
Interchangeable products
Decadron · DIN 00213624 · not recorded Dexamethasone Sodium · DIN 01977547 · $1.6900
Shortage status: shortage reported ended 2026-09-08 (report last updated 2026-09-08); confirm supply with the pharmacy · Tier 3; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00664227
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Dexamethasone Sodium · DIN 01977547 · 4mg/mL · injection solution

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dexamethasone Sodium · DIN 01977547 Manufacturer: Sterimax Inc.; listing date 1996-12-19 Health Canada: Marketed since 2015-07-31 · brand DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP · ATC H02AB02 DEXAMETHASONE · form Solution · route Intra-articular, Intramuscular, Intravenous · ingredients DEXAMETHASONE PHOSPHATE (DEXAMETHASONE SODIUM PHOSPHATE) 4 MG/ML · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Dexamethasone Sodium: Formulary list price $1.6900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13255 · Verify on the e-Formulary ↗ (DIN 01977547)

Source record
DIN 01977547: Dexamethasone Sodium Raw flags: sec3=Y Item: 680400005; group id 708; item number 1748; lccId None; manufacturer id STE Source form: Inj Sol; strength: 4mg/mL Recorded listing: General benefit Source prices (unrounded): $1.6900; ministry $1.6900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01977547 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13255
Interchangeable products
Decadron · DIN 00213624 · not recorded Dexamethasone Sodium · DIN 00664227 · $1.6900
Shortage status: active shortage (reported 2026-04-10, estimated to end 2026-11-30, last updated 2026-08-19) · Tier 3; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01977547
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Decadron · DIN 00213624 · 4mg/mL · injection solution

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-08-01 — choose a marketed DIN from the same-category list.Discontinued 2001-08-01 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-08-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-08-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Decadron · DIN 00213624 Manufacturer: Merck Sharp & Dohme Canada, Division of Merck Frosst Canada; listing date 1996-10-01 Health Canada: Cancelled post market since 2001-08-01 · brand DECADRON PHOSPHATE INJ 4MG/ML · ATC H02AB02 DEXAMETHASONE · form Liquid · route Intravenous, Intramuscular · ingredients DEXAMETHASONE SODIUM PHOSPHATE 4 MG/ML · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Check this DIN again · Health Canada product record

Decadron: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1369 · Verify on the e-Formulary ↗ (DIN 00213624)

Source record
DIN 00213624: Decadron Raw flags: notABenefit=Y, sec3=Y Item: 680400005; group id 708; item number 1748; lccId None; manufacturer id MSD Source form: Inj Sol; strength: 4mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00213624 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1369
Interchangeable products
Dexamethasone Sodium · DIN 00664227 · $1.6900 Dexamethasone Sodium · DIN 01977547 · $1.6900
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00213624
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2001-08-01 — choose a marketed DIN from the same-category list.

CIPROFLOXACIN AND DEXAMETHASONE

All strengths: Limited Use — Reason for Use code 509 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 509 required
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (H02AB, S01BA) — coverage varies; not interchangeable

  • Fluorometholone (Fml): general benefit
  • Fluorometholone (Flarex): general benefit
  • Hydrocortisone (Cortef): general benefit, Listing status unconfirmed
  • Methylprednisolone (Medrol): general benefit
  • Methylprednisolone (Depo-Medrol): general benefit
  • Prednisolone (Pred Forte): general benefit, Not a benefit

7 more in the class list below

Ciprodex · DIN 02252716 · 0.3% w/v & 0.1% w/v · Otic suspension-7.5mL Pk (With Preservative)

Limited Use — Reason for Use code 509 requiredMarketed · checked 2026-09-02
Write on scriptLU code 509 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 509
Reason for Use code 509 The treatment of otitis externa in patients: - With known perforated tympanic membrane or ventilation tubes; OR - Requiring chronic therapy (i.e., more than 14 days); OR - Who have been receiving more than 7 days of topical aminoglycoside therapy without improvement, where there is concern of a resistant pathogen; OR - With documented pre-existing hearing impairment. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Ciprodex · DIN 02252716 Manufacturer: Novartis Pharma Canada Inc.; listing date 2018-06-29 Health Canada: Marketed since 2018-06-11 · brand CIPRODEX · ATC S02CA06 DEXAMETHASONE AND ANTIINFECTIVES, S02CA06 DEXAMETHASONE AND ANTIINFECTIVES · form Suspension · route Otic · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 0.3 %/W/V, DEXAMETHASONE 0.1 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $14.4203 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73758 · Verify on the e-Formulary ↗ (DIN 02252716)

Source record
DIN 02252716: Ciprodex Raw flags: sec12=Y, sec3=Y Item: 520404046; group id 575; item number 1529; lccId 00306; manufacturer id NOV Source form: Otic Susp-7.5mL Pk (With Preservative); strength: 0.3% w/v & 0.1% w/v Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $32.6094; ministry $14.4203 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02252716 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73758
Interchangeable products
Sandoz Ciprofloxacin/Dexamethasone · DIN 02506882 · $14.4203 Taro-Ciprofloxacin/Dexamethasone · DIN 02481901 · $14.4203
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02252716
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Ciprofloxacin/Dexamethasone · DIN 02506882 · 0.3% w/v & 0.1% w/v · Otic suspension-7.5mL Pk (With Preservative)

Limited Use — Reason for Use code 509 requiredMarketed · checked 2026-09-02
Write on scriptLU code 509 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 509
Reason for Use code 509 The treatment of otitis externa in patients: - With known perforated tympanic membrane or ventilation tubes; OR - Requiring chronic therapy (i.e., more than 14 days); OR - Who have been receiving more than 7 days of topical aminoglycoside therapy without improvement, where there is concern of a resistant pathogen; OR - With documented pre-existing hearing impairment. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Ciprofloxacin/Dexamethasone · DIN 02506882 Manufacturer: Sandoz Canada Inc.; listing date 2021-03-29 Health Canada: Marketed since 2021-01-26 · brand SANDOZ CIPROFLOXACIN / DEXAMETHASONE · ATC S02CA06 DEXAMETHASONE AND ANTIINFECTIVES, S02CA06 DEXAMETHASONE AND ANTIINFECTIVES · form Suspension · route Otic · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 0.3 %/W/V, DEXAMETHASONE 0.1 %/W/V · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Ciprofloxacin/Dexamethasone: Formulary list price $14.4203/unit (unit not stated in source; not the patient's cost)

Ministry pays: $14.4203 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99623 · Verify on the e-Formulary ↗ (DIN 02506882)

Source record
DIN 02506882: Sandoz Ciprofloxacin/Dexamethasone Raw flags: sec12=Y, sec3=Y Item: 520404046; group id 575; item number 1529; lccId 00306; manufacturer id SDZ Source form: Otic Susp-7.5mL Pk (With Preservative); strength: 0.3% w/v & 0.1% w/v Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.4203; ministry $14.4203 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02506882 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99623
Interchangeable products
Ciprodex · DIN 02252716 · $14.4203 Taro-Ciprofloxacin/Dexamethasone · DIN 02481901 · $14.4203
Shortage status: resolved shortage (ended 2025-05-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02506882
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Ciprofloxacin/Dexamethasone · DIN 02481901 · 0.3% w/v & 0.1% w/v · Otic suspension-7.5mL Pk (With Preservative)

Limited Use — Reason for Use code 509 requiredMarketed · checked 2026-09-02
Write on scriptLU code 509 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 509
Reason for Use code 509 The treatment of otitis externa in patients: - With known perforated tympanic membrane or ventilation tubes; OR - Requiring chronic therapy (i.e., more than 14 days); OR - Who have been receiving more than 7 days of topical aminoglycoside therapy without improvement, where there is concern of a resistant pathogen; OR - With documented pre-existing hearing impairment. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Ciprofloxacin/Dexamethasone · DIN 02481901 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2020-12-18 Health Canada: Marketed since 2020-11-23 · brand TARO-CIPROFLOXACIN/DEXAMETHASONE · ATC S02CA06 DEXAMETHASONE AND ANTIINFECTIVES, S02CA06 DEXAMETHASONE AND ANTIINFECTIVES · form Suspension · route Otic · ingredients DEXAMETHASONE 0.1 %/W/V, CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 0.3 %/W/V · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Ciprofloxacin/Dexamethasone: Formulary list price $14.4203/unit (unit not stated in source; not the patient's cost)

Ministry pays: $14.4203 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97239 · Verify on the e-Formulary ↗ (DIN 02481901)

Source record
DIN 02481901: Taro-Ciprofloxacin/Dexamethasone Raw flags: sec12=Y, sec3=Y Item: 520404046; group id 575; item number 1529; lccId 00306; manufacturer id TAR Source form: Otic Susp-7.5mL Pk (With Preservative); strength: 0.3% w/v & 0.1% w/v Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.4203; ministry $14.4203 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02481901 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97239
Interchangeable products
Ciprodex · DIN 02252716 · $14.4203 Sandoz Ciprofloxacin/Dexamethasone · DIN 02506882 · $14.4203
Shortage status: active shortage (reported 2026-03-04, estimated to end 2026-09-25, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02481901
Shortage record checked 2026-09-13T08:10:21.292534+00:00

FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE

All products: general benefit

Other products in the same Health Canada class (H02AB, S01BA) — coverage varies; not interchangeable

  • Fluorometholone (Fml): general benefit
  • Fluorometholone (Flarex): general benefit
  • Hydrocortisone (Cortef): general benefit, Listing status unconfirmed
  • Methylprednisolone (Medrol): general benefit
  • Methylprednisolone (Depo-Medrol): general benefit
  • Prednisolone (Pred Forte): general benefit, Not a benefit

7 more in the class list below

Sofracort · DIN 02224623 · 5mg & 50mcg & 0.5mg/mL · Oph/Ot Sol

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Sofracort · DIN 02224623 Manufacturer: Sanofi Aventis Pharma; listing date 2001-10-11 Health Canada: Marketed since 2024-07-30 · brand SOFRACORT · ATC S03CA01 DEXAMETHASONE AND ANTIINFECTIVES, S03CA01 DEXAMETHASONE AND ANTIINFECTIVES · form Drops · route Otic, Ophthalmic · ingredients FRAMYCETIN SULFATE 5 MG/ML, GRAMICIDIN 0.05 MG/ML, DEXAMETHASONE (DEXAMETHASONE SODIUM METASULPHOBENZOATE) 0.5 MG/ML · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Sofracort: Formulary list price $2.2212/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.2212 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37363 · Verify on the e-Formulary ↗ (DIN 02224623)

Source record
DIN 02224623: Sofracort Raw flags: sec3=Y Item: 520404012; group id 577; item number 1532; lccId None; manufacturer id SAV Source form: Oph/Ot Sol; strength: 5mg & 50mcg & 0.5mg/mL Recorded listing: General benefit Source prices (unrounded): $2.2212; ministry $2.2212 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02224623 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37363 Therapeutic Notes (formulary) The risk of ototoxicity with topical aminoglycoside may increase with prolonged therapy. Topical use of antibiotics increases the likelihood of development of bacterial resistance, especially with prolonged use, sometimes rendering the systemic use of this antibiotic class useless in these patients.
Shortage status: resolved shortage (ended 2025-10-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02224623
Shortage record checked 2026-09-13T08:10:21.292534+00:00

TOBRAMYCIN & DEXAMETHASONE

Form:

2 of 2 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (H02AB, S01BA) — coverage varies; not interchangeable

  • Fluorometholone (Fml): general benefit
  • Fluorometholone (Flarex): general benefit
  • Hydrocortisone (Cortef): general benefit, Listing status unconfirmed
  • Methylprednisolone (Medrol): general benefit
  • Methylprednisolone (Depo-Medrol): general benefit
  • Prednisolone (Pred Forte): general benefit, Not a benefit

7 more in the class list below

TobraDex · DIN 00778915 · 0.3% & 0.1% · Oph Oint

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
TobraDex · DIN 00778915 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-04-26 · brand TOBRADEX · ATC S01CA01 DEXAMETHASONE AND ANTIINFECTIVES, S01CA01 DEXAMETHASONE AND ANTIINFECTIVES · form Ointment · route Ophthalmic · ingredients TOBRAMYCIN 0.3 %/W/W, DEXAMETHASONE 0.1 %/W/W · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

TobraDex: Formulary list price $3.3171/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.3171 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10971 · Verify on the e-Formulary ↗ (DIN 00778915)

Source record
DIN 00778915: TobraDex Raw flags: sec3=Y Item: 520404032; group id 585; item number 1541; lccId None; manufacturer id NOV Source form: Oph Oint; strength: 0.3% & 0.1% Recorded listing: General benefit Source prices (unrounded): $3.3171; ministry $3.3171 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00778915 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10971
Shortage status: resolved shortage (ended 2025-08-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00778915
Shortage record checked 2026-09-13T08:10:21.292534+00:00

TobraDex · DIN 00778907 · 0.3% & 0.1% · Oph suspension

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
TobraDex · DIN 00778907 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-05-10 · brand TOBRADEX · ATC S01CA01 DEXAMETHASONE AND ANTIINFECTIVES, S01CA01 DEXAMETHASONE AND ANTIINFECTIVES · form Suspension · route Ophthalmic · ingredients DEXAMETHASONE 0.1 %/W/V, TOBRAMYCIN 0.3 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

TobraDex: Formulary list price $2.2500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.2500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11068 · Verify on the e-Formulary ↗ (DIN 00778907)

Source record
DIN 00778907: TobraDex Raw flags: sec3=Y Item: 520404031; group id 585; item number 1542; lccId None; manufacturer id NOV Source form: Oph Susp; strength: 0.3% & 0.1% Recorded listing: General benefit Source prices (unrounded): $2.2500; ministry $2.2500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00778907 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11068
Shortage status: resolved shortage (ended 2022-08-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00778907
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (52:04:04 Antibiotics) and how they are covered

Matched class: 52:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FRAMYCETIN SULFATE, GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE, GENTAMICIN SULFATE, POLYMYXIN B SULFATE & BACITRACIN (ZINC), POLYMYXIN B SULFATE & GRAMICIDIN, TOBRAMYCIN 52:04:04 Antibiotics

FRAMYCETIN SULFATE

· 2 products · General benefit · strengths: 0.5% · Oph Oint-5g Pk, Oph Sol

GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE

· 1 products · General benefit · strengths: 3mg & 1mg/mL · Oph/Ot Drops

GENTAMICIN SULFATE

· 1 products · General benefit · strengths: 0.3% · Oph Oint-3.5g Pk

POLYMYXIN B SULFATE & BACITRACIN (ZINC)

· 1 products · General benefit · strengths: 10000U & 500U/g · Oph Oint 3.5g Pk

POLYMYXIN B SULFATE & GRAMICIDIN

· 1 products · General benefit · strengths: 10000U & 0.025mg/mL · Oph/Ot Sol

TOBRAMYCIN

· 3 products · General benefit · strengths: 0.3% · Oph Oint, Oph Sol

GATIFLOXACIN

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.3% w/v · Oph Sol

MOXIFLOXACIN HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5% · Oph Sol-3mL Pk (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:04:04
Full class listing Related classes: 52:04:12 Other Anti-Infectives, 52:08:92 Anti-Inflammatory Agents, Miscellaneous

Other drugs in the same formulary class (52:08 Anti-Inflammatory Agents) and how they are covered

Matched class: 52:08 Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN, FLUOROMETHOLONE, FLUOROMETHOLONE ACETATE, KETOROLAC TROMETHAMINE, LODOXAMIDE TROMETHAMINE Some products covered without a code (check the product listing): BECLOMETHASONE DIPROPIONATE, BUDESONIDE, PREDNISOLONE ACETATE 52:08 Anti-Inflammatory Agents

FLUOROMETHOLONE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

FLUOROMETHOLONE ACETATE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

PREDNISOLONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Oph Susp

KETOROLAC TROMETHAMINE

· 3 products · General benefit · strengths: 0.5%, 0.45% w/v · Oph Sol, Oph Sol-0.4mL Vial Pk (Preservative-Free)

BROMFENAC

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.07% w/v · Oph Sol (With Preservative)

BECLOMETHASONE DIPROPIONATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 50mcg · Nas-Sp-200 Dose Pk

BUDESONIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 64mcg/Metered Dose, 100mcg/Metered Dose · Nas Sp-120 Dose Pk, Nas Sp-165 Dose Pk

FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN

· 1 products · General benefit · strengths: 0.02% & 1% · Ot Sol

LODOXAMIDE TROMETHAMINE

· 1 products · General benefit · strengths: 0.1% · Oph Sol

AZELASTINE HCL & FLUTICASONE PROPIONATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 137mcg/Actuation&50mcg/Actuation · Nas-Sp-120 Dose Pk

FLUTICASONE PROPIONATE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Actuation · Nas Sp-120 Dose Pk

MOMETASONE FUROATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Dose · Nas Sp-140 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:08 and 2 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors, 52:36 Other Eye, Ear, Nose and Throat Agents

Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

PREDNISOLONE SODIUM PHOSPHATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L

PREDNISONE

· 7 products · General benefit (5), Listed, not a benefit (2) · strengths: 1mg, 5mg, 50mg · Tab

TRIAMCINOLONE ACETONIDE

· 3 products · General benefit · strengths: 40mg/mL, 50mg/5mL, 200mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

TRIAMCINOLONE HEXACETONIDE

· 1 products · Limited Use, codes 580 · strengths: 20mg/mL · 1mL-Amp Pk

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 4 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CLARITHROMYCIN · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (15), Off-Formulary Interchangeable, not an ODB benefit (9) (For additional information on the use of BIAXIN BID® in triple therapy for the treatment of H. pylori infection and active duodenal ulcer recurrence, refer to the Hp-PAC® Product Monograph.) BIAXIN® (clarithromycin for oral suspension USP) Product Monograph Master Template Template Date: September 2020 BIAXIN BID®, BIAXIN® - clarithromycin Page 4 of 107 BIAXIN® is indicated for the treatment of infections due to susceptible organisms, in the following conditions: • Upper Respiratory Tract • Pharyngitis caused by S. pyogenes (Group A ß-hemolytic streptococci). PM: https://pdf.hres.ca/dpd_pm/00078094.PDF; date DEC 17, 2024; DIN 01984853; fetched 2026-09-10 Product monograph TETRACYCLINE · Listed, not a benefit (1), General benefit (1) Indications TETRACYCLINE (tetracycline hydrochloride capsules) is indicated for infections caused by the following microorganisms: • Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, tick fevers), M. pneumoniae (PPLO, Eaton agent), agents of psittacosis and ornithosis, agents of L. venereum and G. inguinale, and the spirochetal agent of relapsing fever (B. recurrentis). PM: https://pdf.hres.ca/dpd_pm/00084169.PDF; date 2026-03-17; DIN 00580929; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS MAXIDEX® (dexamethasone ophthalmic ointment, USP and dexamethasone ophthalmic suspension, BP) is indicated for: • Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, iritis, cyclitis, and selected infective conjunctivitis when the inherit hazard of steroid use is acceptable to obtain an advisable diminution in edema and inflammation. • Corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. 1.1 Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of MAXIDEX in children have not been established. 1.2 Geriatrics Geriatrics (> 60 years of age): No overall differences in safety or effectiveness have been observed between elderly and younger patients. https://pdf.hres.ca/dpd_pm/00072175.PDF PM date: April 01, 2001 Source product: MAXIDEX; DIN 00042560; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Dexamethasone Sodium Phosphate Injection USP may be given by IV or IM injection when oral therapy is not feasible in the following conditions: Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic glucocorticoids may be used in conjunction with a mineralocorticoid where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic glucocorticoids are used). Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Rheumatic Disorders: As adjunctive therapy for short term administration (to support the patient during an acute period of exacerbation) in post-traumatic osteoarthritis, synovitis of osteoarthritis, rheumatoid arthritis,… https://pdf.hres.ca/dpd_pm/00083916.PDF PM date: March 17, 2026 Source product: DEXAMETHASONE SODIUM PHOSPHATE INJ USP 4MG/ML; DIN 00664227; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE CIPRODEX® (ciprofloxacin/dexamethasone otic suspension) is indicated for the treatment of infections caused by most strains of the designated microorganisms in the specific conditions listed below: Acute Otitis Media with Otorrhea through tympanostomy tubes in pediatric patients ≥ 6 months of age due to: Aerobic, Gram-Positive: Streptococcus pneumoniae Staphylococcus aureus Aerobic, Gram-Negative: Haemophilus influenza Moraxella catarrhalis Pseudomonas aeruginosa Acute Otitis Externa in adults and pediatric patients ≥ 1 year of age due to: Aerobic, Gram-Positive: Staphylococcus aureus Aerobic, Gram-Negative: Pseudomonas aeruginosa To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRODEX and other antibacterial drugs, CIPRODEX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. CIPRODEX® Product Monograph Page 3 of 20 Geriatrics (> 65 years of age): Elderly patients may be at a higher risk of developing tendon inflammation and rupture (see WARNINGS AND PRECAUTIONS, General). Pediatrics (… https://pdf.hres.ca/dpd_pm/00041611.PDF PM date: September 27, 2017 Source product: CIPRODEX; DIN 02252716; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS SOFRACORT (framycetin sulfate, dexamethasone and gramicidin ophthalmic/otic solution) is indicated for: • Eye: Blepharitis and infected eczema of the eyelid; allergic, infective and rosacea conjunctivitis; rosacea keratitis; scleritis and episcleritis; iridocyclitis, and other inflammatory conditions of the anterior segment of the eye. • Ear: Otitis externa (acute and chronic) and other inflammatory and seborrheic conditions of the external ear. SOFRACORT contains antibacterial ingredients, framycetin and gramicidin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of framycetin and gramicidin, SOFRACORT should only be used for the authorized indication. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00076258.PDF PM date: not printed or not captured Source product: SOFRACORT; DIN 02224623; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TOBRADEX® (tobramycin and dexamethasone ophthalmic suspension and ointment) is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exist. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, thermal burns or penetration of foreign bodies. To reduce the development of drug-resistant bacteria and maintain the effectiveness of TOBRADEX and other antibacterial drugs, TOBRADEX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Pediatrics (< 18 years of age): The safety and effectiveness of TOBRADEX have not been established in pediatric patients. TOBRADEX® Product Monograph Page 3 of 28 https://pdf.hres.ca/dpd_pm/00055027.PDF PM date: February 12, 2020 Source product: TOBRADEX; DIN 00778907; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Dexamethasone Sodium · DIN 00664227 Shortage status: shortage reported ended 2026-09-08 (report last updated 2026-09-08); confirm supply with the pharmacy · Tier 3; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00664227

Check this DIN again

Dexamethasone Sodium · DIN 01977547 Shortage status: active shortage (reported 2026-04-10, estimated to end 2026-11-30, last updated 2026-08-19) · Tier 3; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01977547

Check this DIN again

Taro-Ciprofloxacin/Dexamethasone · DIN 02481901 Shortage status: active shortage (reported 2026-03-04, estimated to end 2026-09-25, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02481901

Check this DIN again

Other review policies

For Decadron: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026